Search Results
Jan 01, 2026, 04:35 ET Alaska Airlines' New Year's at the Needle Celebration Delights West Coast Viewers, Welcoming 2026
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."About KING 5KING 5 Media Group is a multi-platform media company based in Seattle, WA. It includes NBC affiliate KING 5, independent
More news about: Space Needle
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
chemotherapy;For the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations;For the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer
More news about: Innovent Biologics
Dec 22, 2025, 06:30 ET Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
More news about: Nuvalent, Inc.
Dec 19, 2025, 17:19 ET Alaska Airlines to Resume Nonstop Service Between Paine Field and Portland Beginning June 2026
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."About Propeller AirportsBased in Everett, Washington, Propeller identifies untapped potential for
More news about: Propeller Airports; Alaska Air Group
Dec 19, 2025, 09:00 ET Alaska Air Group welcomes Ryan Sather as new vice president of safety and security
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Dec 18, 2025, 08:00 ET Alaska Airlines bolsters service from Anchorage and Portland with seven new routes, including nonstop flights to Boston, Jackson Hole and four Washington state cities
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Dec 18, 2025, 01:09 ET Благодаря прецизионной онкологии 69-летняя пациентка из Казахстана возвращает свою жизнь, принимая ежедневно одну таблетку
опухолевая ткань пациентки подверглась комплексному геномному профилированию. Комплексное геномное профилирование тканевого образца выявило слияние EML4-ALK, аномалию генов с предсказуемым ответом на таргетную терапию. Вместо химиотерапии или лучевой терапии ей назначали таргетную терапию, заключающуюся
More news about: Apollo Athenaa
Dec 18, 2025, 01:08 ET 69-Year-Old Patient from Kazakhstan Reclaims Her Life with a Single Daily Pill Through Precision Oncology
Following a biopsy, her tumour tissue underwent comprehensive genomic profiling. Comprehensive genomic profiling of the tissue biopsy identified an EML4-ALK fusion, an alteration predictive of response to targeted therapy. Instead of chemotherapy or radiotherapy, she was placed on a targeted therapy regimen
More news about: Apollo Athenaa
Dec 17, 2025, 13:00 ET Hawaiian and Alaska airlines, Par Hawaii and Pono Energy partner to advance the Hawai'i-based market, supply chain for sustainable aviation fuel production
Learn more about what's happening at Alaska and Hawaiian at news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."About Par HawaiiPar Hawaii is the state's leading provider of transportation fuels. It is headquartered in Honolulu and
More news about: Hawaiian Airlines
Dec 16, 2025, 19:19 ET Allink Biotherapeutics completa rondas de extensión de la Serie A por 47 millones de dólares
potencial terapéutico de ambos activos en poblaciones más amplias de pacientes de primera línea. Estas iniciativas acelerarán la preparación de ALK201 y ALK202 para ensayos clínicos cruciales, a la vez que establecerán un perfil diferenciado en sus respectivas indicaciones objetivo.Aumento
More news about: Allink Biotherapeutics
Dec 16, 2025, 08:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
therapy studies to further explore the two assets' therapeutic potential in broader front-line patient populations. These initiatives will accelerate ALK201 and ALK202 toward pivotal trial readiness while establishing a differentiated profile in their respective target indications.Augmenting Novel
More news about: Allink Biotherapeutics
Dec 16, 2025, 02:30 ET Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
therapy studies to further explore the two assets' therapeutic potential in broader front-line patient populations. These initiatives will accelerate ALK201 and ALK202 toward pivotal trial readiness while establishing a differentiated profile in their respective target indications.Augmenting Novel
More news about: Allink Biotherapeutics
Dec 16, 2025, 02:30 ET Allink Biotherapeutics schließt eine Finanzierungsrunde der Serie A in Höhe von 47 Millionen US-Dollar ab, um klinische Programme und die Entwicklung neuartiger Plattformen voranzutreiben
therapeutische Potenzial der beiden Wirkstoffe in einer breiteren Patientengruppe weiter zu untersuchen. Diese Initiativen werden die Vorbereitung von ALK201 und ALK202 für die zulassungsrelevanten Studien beschleunigen und gleichzeitig ein differenziertes Profil in ihren jeweiligen Zielindikationen etablieren.Erweiterung
More news about: Allink Biotherapeutics
Dec 16, 2025, 02:30 ET Allink Biotherapeutics conclut des tours de table supplémentaires de 47 millions de dollars de la série A pour accélérer les programmes cliniques et le développement de nouvelles plates-formes
produits dans des populations de patients de première ligne plus larges. Ces initiatives permettront d'accélérer la préparation des essais pivots pour ALK201 et ALK202 tout en établissant un profil différencié dans leurs indications cibles respectives.Augmenter les capacités des plates-formes de nouvelles
More news about: Allink Biotherapeutics
Dec 15, 2025, 19:30 ET 安領科生物完成近5000萬美元A輪追加融資，加速ADC項目全球臨床及創新技術平台開發
輪追加融資分別由老股東君聯資本與新晉投資方美團龍珠領投，藍馳創投、元生創投、五源資本、龍磐投資、潤璋創投等多家知名新老股東跟投。 全面推進兩大核心產品的全球臨床開發本輪 A 輪擴展融資，將助力加速推進公司兩款具有顯著差異化優勢的核心管線的全球臨床開發。ALK201 作為一款有望成為「同類首創」且「同類最佳」的靶向 FGFR2b 的 ADC 藥物，已在多種腫瘤類型中展現出令人鼓舞的療效信號及良好的安全性，為其成為 FGFR2b 過表達實體瘤的基石療法奠定了堅實基礎。同步推進的 ALK202 項目，其早期臨床數據也初步驗證了這款 EGFR/cMET 雙特異性 ADC 有望樹立非小細胞肺癌治療領域的新一代治療標桿。此外，該項目正
More news about: Allink Biotherapeutics
Dec 11, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alaska Air Group, Inc. - ALK
2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alaska Air Group, Inc. ("Alaska Air" or the "Company") (NYSE: ALK). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Dec 11, 2025, 08:05 ET ALLEGRIA THERAPEUTICS SECURES USD 5.1 MILLION SEED EXTENSION FINANCING
journey." ALK-Abelló (ALK), a global specialty pharmaceutical company focused on allergy and allergic asthma, is providing ALLEGRIA with a strong partner in the allergy space. Peter Sejer Andersen, Ph.D., Senior Vice President of Global Research and Drug Discovery at ALK says: "Every
More news about: Allegria Therapeutics AG
Dec 10, 2025, 16:01 ET Nuvalent Appoints Ron Squarer to Board of Directors
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.Forward-Looking StatementsThis
More news about: Nuvalent, Inc.
Dec 10, 2025, 09:00 ET New Year's at the Needle Returns: The West Coast Window to the World
Learn more about what's happening at Alaska and Hawaiian at news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."About KING 5 KING 5 Media Group is a multi-platform media company based in Seattle, WA. It includes NBC affiliate KING 5, independent
More news about: Space Needle
Dec 09, 2025, 08:00 ET Alaska Airlines is now selling tickets for new nonstop flights between Seattle and London Heathrow on Boeing 787 Dreamliner aircraft
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Dec 06, 2025, 15:40 ET Zenocutuzumab-zbco (BIZENGRI®) Shows Durable Efficacy in Patients with Treatment-Naïve NRG1+NSCLC: Updated eNRGy Trial Results Presented at IASLC-ASCO NACLC
FusionsNRG1 fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activate downstream signaling pathways that
More news about: Partner Therapeutics, Inc.
Dec 03, 2025, 08:31 ET Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
he oversaw major pharmaceutical commercialization efforts. Currently, Mr. Høiland serves as Chairman of SciBase Holding AB and is a board member of ALK-Abell ó A/S, Flen Health SA, and Allarity Therapeutics."It is my distinct pleasure to welcome Jesper Høiland to the Alva Board of Directors,"
More news about: Alva Therapeutics
Dec 02, 2025, 09:03 ET Alaska Airlines and Hawaiian Airlines Soar to the Top of Thanksgiving Travel
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Nov 27, 2025, 17:31 ET Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight
clinical trials.Novel Agents and Immuno-Oncology Approaches for Relapsed or Metastatic RhabdomyosarcomaNew drugs targeting IGF1R, ALK, and FGFR pathways, as well as immune-based strategies such as checkpoint inhibitors, CAR-T cells, and cancer vaccines, hold promise for improving outcomes
More news about: DelveInsight Business Research LLP
Nov 26, 2025, 06:30 ET Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference
brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
More news about: Nuvalent, Inc.